EML4 and cancer: ALK fusions, including EML4–ALK, TFG–ALK and STRN–ALK, have been identified in multiple cancer types, including lung adenocarcinoma3, colorectal4, breast5, renal cell6, renal medullary7 and thyroid cancers8.